🫁 Understanding Chronic Cough in Aspergillosis

What the latest British Thoracic Society statement means for you

🌬️ Why This Matters

If you live with aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), or bronchiectasis, coughing can dominate your life. It’s tiring, painful, and socially awkward — especially when people assume it means infection.

Doctors used to see cough as just a symptom of another problem, but the British Thoracic Society (BTS) Clinical Statement on Chronic Cough in Adults (2023) recognises something new:

For many people, a cough can become a condition in its own right — caused by airway and nerve hypersensitivity, not just infection.

This matters for aspergillosis patients because fungal allergy and inflammation make the airways especially sensitive.

💡 What Is “Chronic Cough”?

A chronic cough is one lasting eight weeks or more.
It may be:

Dry – little or no mucus
Productive – thick sputum (common in bronchiectasis or chronic aspergillosis)
Triggered by dust, cold air, perfume, or strong scents

For people with aspergillosis, several overlapping causes may exist:

Fungal colonisation or infection
Allergic inflammation (ABPA)
Bronchiectasis and mucus retention
Reflux or post-nasal drip
Nerve hypersensitivity

This is why one treatment rarely fixes everything — different “treatable traits” must be addressed together.

🧬 Why It Happens

1️⃣ The Hypersensitive Cough Reflex

People with aspergillosis often develop overactive airway nerves — so normal irritants like dust, scent, or cold air trigger coughing fits.

This “cough reflex hypersensitivity” happens because:

Ongoing inflammation damages the airway lining.
Nerve endings in the throat and lungs become over-responsive.
Even mild triggers set off powerful reflexes.

This is a real physiological process, not psychological.
It’s why cough can continue even when infection is under control.

2️⃣ Treatable Traits – Finding the Real Drivers

Treatable Trait	What It Means	What Helps
Airway infection or colonisation	Persistent fungi or bacteria	Antifungal or antibiotic therapy, sputum tests
Allergic inflammation	ABPA or asthma-type airway swelling	Corticosteroids, biologics (e.g., mepolizumab, benralizumab)
Cough reflex hypersensitivity	Overactive airway nerves	Speech therapy, nerve-modulating medication
Airway clearance problems	Mucus that’s hard to shift	Physiotherapy, saline or mucolytic therapy
Reflux or postnasal drip	Acid or sinus drainage irritation	Reflux management, ENT care

Identifying these traits helps your clinician personalise treatment.

💊 Medications That Can Cause or Worsen Cough

The BTS statement highlights that some medicines can trigger or amplify chronic cough — especially in people with already-sensitive lungs.

🔹 ACE Inhibitors (Blood pressure or heart disease)

Examples: Ramipril, Lisinopril, Enalapril, Perindopril

Can cause a dry, tickly cough due to bradykinin build-up.
Happens in ~1 in 5 users, sometimes months after starting.
GP can switch to a similar drug (ARB – e.g., losartan) that doesn’t cause cough.

🔹 Beta Blockers (Heart or migraine medicines)

Examples: Atenolol, Propranolol, Bisoprolol

May tighten airways, worsening wheeze or cough.
Safer “lung-selective” versions exist but should still be monitored.

🔹 Inhalers

Examples: Fluticasone, Budesonide, Salbutamol

Can irritate the throat if used without a spacer or if technique is poor.
Always rinse or gargle after use, and ask your pharmacist to review inhaler technique.

🔹 Antifungal or Reflux Medicines

Antifungals (itraconazole, voriconazole) don’t directly cause cough, but reflux or nausea can trigger coughing indirectly.
PPIs (omeprazole, lansoprazole) usually help reflux-related cough, but long-term use should be reviewed regularly.

🔹 Other Drugs

Amiodarone, methotrexate, and some biologics can rarely cause cough due to lung inflammation.
Nasal sprays or lozenges with menthol/alcohol may irritate already-sensitive airways.

💬 If you suspect a medicine is contributing, don’t stop it suddenly — speak to your doctor or pharmacist first.
They can review interactions using the
👉 BNF Interactions Checker – NICE Medicines Guidance.

🔍 How Doctors Assess Chronic Cough

BTS recommends a structured pathway:

Basic tests: chest X-ray, spirometry, bloods (eosinophils, IgE), FeNO if available.
Further tests: CT scan, allergy or sputum studies if initial tests are abnormal.
Trait-based review: identifying overlapping issues — fungal, allergic, nerve-related, or reflux-related.
Specialist referral: to a Cough Clinic or Aspergillosis Centre if symptoms persist.

🧴 Pharmacists: Your Safety Specialists

Pharmacists — hospital or community — are crucial for managing long-term cough and medication safety:

Check for cough-inducing drugs or interactions.
Advise on best timing for antifungal and steroid doses.
Help switch to fragrance-free personal or cleaning products.
Liaise with your GP and consultant to fine-tune treatment.

🧭 Regular medication reviews every few months can prevent small problems becoming major triggers.

💬 How It Feels — and Why It’s Misunderstood

People with aspergillosis often describe:

“A tickle that turns into a spasm I can’t stop.”
“People think I’m ill, but it’s just the air or perfume.”

This happens because your airway nerves and immune cells are already primed.
Coughing doesn’t mean you’re infectious — it’s your body’s protective reflex in overdrive.

🩺 What Helps Most

Optimise your aspergillosis and ABPA treatment.
Cough-control physiotherapy or speech therapy for nerve-related cough.
Airway clearance techniques for mucus.
Identify and avoid irritants: perfume, smoke, strong detergents, cold air.
Ask about biologics if inflammation remains active despite steroids.
Use nerve-modulating medicines only under specialist advice.

🧘 Emotional Health Matters Too

Living with a chronic cough can cause anxiety, embarrassment, and isolation.
Support from counsellors, CBT therapists, or patient groups helps manage this stress — and can actually reduce cough frequency through better relaxation and breathing control.

🌱 Key Takeaway

Chronic cough in aspergillosis isn’t “just a symptom” — it’s often a mix of airway inflammation, fungal allergy, nerve hypersensitivity, and sometimes side effects of medicines.

The good news is that every contributing factor is treatable once identified — and cough can improve significantly with the right combination of medical, physical, and environmental care.

🔗 Trusted Resources

by GAtherton

🧩 NAC Aspergillosis Research Digest Aspergillosis (October 2025: week 44)

Highlights

Pulmonary aspergillosis in chronic lung disease can be severe and life-threatening, especially in patients with underlying interstitial lung conditions. Prompt diagnosis and subtype-targeted treatment are crucial for better outcomes (7).
Advanced sinus imaging in dogs improves veterinary precision for diagnosing and treating fungal infections such as aspergillosis (1).
Poultry farms in Turkey are best protected against aspergillosis outbreaks through consistent hygiene and environment management (3).
Pediatric liver transplant patients remain at high risk of deadly fungal infections, so ongoing immune and drug monitoring is vital (2).
New antifungal agents such as isavuconazole are yielding positive results in children, adults, and drug-resistant cases (10).
Agricultural fungicide use is driving azole resistance in Aspergillus, prompting urgent "One Health" responses across medicine and farming (8).
Research is underway to determine the best antifungal prophylaxis for heart transplant recipients (6).
Case studies show severe treatment challenges for aspergillosis in post-tuberculosis and cancer patients (5), (9).

Pulmonary Aspergillosis in Lung Disease

Recent research examined the prevalence and outcomes of aspergillosis among patients with interstitial lung disease (ILD) and chronic respiratory disorders. The study highlights three major forms:

Invasive Pulmonary Aspergillosis (IPA): Occurs in roughly 2% of hospitalised ILD patients, presenting with symptoms such as fever, persistent cough, and rapid decline in lung function. Those prescribed steroids or immunosuppressants and showing certain lung scan features are at greater risk. Estimated 3-month mortality can reach 50%.
Chronic Cavitary Pulmonary Aspergillosis (CPA): Represents about 0.6% of cases in target populations, with slower onset but significant respiratory impairment over time. Mortality is lower than IPA but remains notable.
Allergic Bronchopulmonary Aspergillosis (ABPA): Occurs in about 3% of studied patients, typically with a better prognosis, though delayed care can worsen outcomes.

Diagnostic strategies involve serology, antigen testing, and imaging to distinguish subtypes and select appropriate antifungal therapy. The study urges multidisciplinary care and more effective protocols for immunosuppressed patients (7).

Veterinary and Animal Health

Advanced radiological mapping now allows veterinarians to better diagnose and treat sinus aspergillosis across various breeds. This enhances surgical accuracy and supports targeted case management (1).
Poultry studies highlight aspergillosis as a leading fungal threat, with hygiene as the most effective control tactic (3).

Human Health: Transplant, Immunosuppression, and Infection

Children undergoing liver transplants require ongoing immune suppression, which increases susceptibility to severe fungal infections like aspergillosis. This underscores the value of rigorous therapeutic monitoring (2).
Current protocols are evaluating which antifungal drugs work best in heart transplant recipients to prevent invasive fungal infections (6)

Clinical Complications and Case Reports

Case studies spotlight life-threatening adrenal crisis and aspergillosis in children recovered from TB and adults with leukaemia. Timely diagnosis and combined therapies are essential for recovery (5), (9)
Transplant patients are vulnerable to bacterial and fungal sinus infections, presenting significant diagnostic challenges (4).

Drug Resistance and Novel Treatments

The rise of azole-resistant Aspergillus, driven by agricultural fungicide use, is making some forms of aspergillosis harder to treat. Integrated medical and environmental interventions are needed to slow resistance (8)
New medications, such as isavuconazole, are being adopted for severe and resistant cases in paediatric and adult populations with positive early results (10).

Reference List

by GAtherton

🧬 The Story of Brensocatib: A New Way to Calm Lung Inflammation

What Is Brensocatib?

Brensocatib is a new type of anti-inflammatory medicine being developed to protect the lungs from long-term damage caused by overactive immune cells, especially neutrophils.
It is being tested by the company Insmed in people with bronchiectasis, but it may also help those with aspergillosis and other chronic lung diseases where inflammation is a major problem.

Brensocatib is taken as a once-daily tablet—not an injection.

Why Was It Developed?

In conditions like ABPA (Allergic Bronchopulmonary Aspergillosis) and CPA (Chronic Pulmonary Aspergillosis), inflammation is often persistent.
The lungs attract neutrophils, which are immune cells that normally destroy germs.
However, when too many neutrophils gather, they release enzymes that damage healthy lung tissue, thicken mucus, and make infection easier for fungi and bacteria.

Researchers realised that if they could turn down the destructive part of neutrophil activity—without turning off the immune system completely—they might be able to break the cycle of inflammation and infection.

How Brensocatib Works

Brensocatib blocks a switch inside the bone marrow called DPP1 (dipeptidyl peptidase-1).
DPP1’s job is to “activate” enzymes inside newly formed neutrophils before they enter the bloodstream.

By blocking DPP1, brensocatib stops neutrophils from producing harmful enzymes such as neutrophil elastase.
These neutrophils can still travel to the lungs and fight infection, but they cause less collateral damage.

👉 In short: brensocatib reduces lung injury caused by over-active immune cells, not by suppressing immunity itself.

Not a Biologic – A Different Type of Treatment

It’s important to understand that brensocatib is not a biologic.

Feature	Biologic drugs (e.g. mepolizumab, dupilumab)	Brensocatib
Made from	Complex proteins or antibodies	Small chemical molecule
How it’s given	Injection or infusion	Oral tablet
What it targets	Specific immune pathways (e.g. IL-5, IL-4)	Enzyme activation in neutrophils
Purpose	Block inflammatory signals	Reduce tissue-damaging enzymes
Typical use	Severe asthma, ABPA, autoimmune diseases	Bronchiectasis, chronic airway inflammation

So, while biologics act by targeting immune messengers in the bloodstream, brensocatib works deeper—at the level of neutrophil development.
The two approaches are different but potentially complementary.
Some people in future may benefit from a combination, depending on their pattern of inflammation.

The Development Story

Early research (2010s): Scientists found that blocking DPP1 prevented lung injury in animal studies.
Insmed’s discovery: Brensocatib was developed as an oral, selective DPP1 inhibitor.
Phase 2 WILLOW trial (2020): In people with bronchiectasis, brensocatib significantly reduced flare-ups and lowered airway inflammation.
Phase 3 ASPEN trial (2022–2025): A large international study now nearing completion; results are expected soon.

If successful, brensocatib could become the first approved DPP1 inhibitor for long-term inflammatory lung disease.

Why This Matters for Aspergillosis Patients

People living with aspergillosis often also have bronchiectasis, where inflammation causes persistent mucus, infection, and breathlessness.
Current treatments such as steroids, antifungals, and biologics can help, but each has limits.

Brensocatib could:

Reduce airway inflammation without steroid side-effects
Protect lung tissue from further damage
Possibly lower the number of flare-ups or infections
Work safely alongside antifungals or biologics

It represents a new way of calming inflammation—by modifying neutrophil behaviour rather than blocking the immune system.

What Happens Next

The ASPEN Phase 3 results are expected soon. If positive, Insmed plans to apply for approval in the UK, EU, and USA.
Researchers are also studying brensocatib in:

COPD (Chronic Obstructive Pulmonary Disease)
Cystic fibrosis
Nontuberculous mycobacterial (NTM) infections

If licensed, it could mark the first new oral anti-inflammatory class for chronic lung disease in decades.

Key Take-Home Messages

Brensocatib reduces harmful lung inflammation by blocking the enzyme DPP1.
It is a small-molecule tablet, not a biologic injection.
It aims to protect the lungs by preventing damage from overactive neutrophils.
It may offer a steroid-sparing option for chronic airway diseases like bronchiectasis and aspergillosis.
It’s currently in final clinical trials, with results expected soon.

💬 Find Out More

National Aspergillosis Centre – aspergillosis.org
Insmed’s brensocatib research
ClinicalTrials.gov – search “brensocatib”

by GAtherton

🧩 NAC Aspergillosis Research Digest — Focus: Chronic Aspergillosis (October 2025: week 42)

🧬 Focus Review — Chronic Aspergillosis (October 2025)

Here are peer-reviewed papers on chronic aspergillosis published in the last month:

1. Improving Diagnostic Sensitivity Using Species-Specific IgG (Sep 2025)

This study investigated better blood tests to diagnose CPA by measuring IgG antibodies not just to Aspergillus fumigatus but also to other common Aspergillus species.
They found adding antibodies against non-fumigatus species identified more CPA cases that would have been missed by the standard A. fumigatus test alone.
The treatment results were similar regardless of which Aspergillus species was involved.
This means broader antibody testing improves diagnosis without changing expected outcomes.
Read full paper on PubMed

2. Prevalence and Impact of Bacterial Co-infections in CPA (April 2025)

This study looked at how often bacterial infections occur alongside CPA and their effect on patients.
About 21% of CPA patients had bacterial co-infections.
However, having a bacterial co-infection did not significantly change mortality rates compared to those without.
This highlights the need to assess for bacteria but suggests it may not worsen long-term outcomes.
Read full paper on PMC

3. Non-invasive Monitoring Using Serology and HRCT Imaging (June 2025)

Researchers combined blood antibody tests and high-resolution chest CT scans to identify active Aspergillus infections in chronic lung disease patients.
This method distinguished active infections from colonization without invasive procedures.
It supports using combined non-invasive tests to decide who needs further invasive diagnostics or antifungal treatment.
This approach helps avoid unnecessary treatments and invasive tests.
Read full paper on Frontiers

In short: these studies improve how doctors diagnose and monitor CPA — by expanding antibody testing beyond classic targets, recognizing the role but limited impact of bacterial co-infections, and using combined non-invasive testing strategies to guide management safely and effectively.

by GAtherton

🧠 Understanding Regulatory T Cells (Tregs) in Aspergillosis

How our immune system’s “brakes” help balance allergy and infection

🏅 2025 Nobel Prize in Medicine: Celebrating a Breakthrough in Immune Regulation

On 6 October 2025, the Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for discovering regulatory T cells (Tregs) and the FOXP3 gene — the master switch that controls immune tolerance.

Their work revealed how the immune system prevents itself from attacking the body’s own tissues. This discovery has since guided the development of immune-modulating therapies now used in cancer, autoimmune, and allergic diseases.

This Nobel recognition highlights how understanding Tregs can lead to smarter, safer therapies — including future immune-based treatments for Allergic Bronchopulmonary Aspergillosis (ABPA) and Chronic Pulmonary Aspergillosis (CPA), where immune balance is disrupted.

🔍 What Are Regulatory T Cells?

Regulatory T cells (Tregs) are a specialised group of white blood cells (lymphocytes) that act as the “brakes” of the immune system.
They prevent excessive inflammation and protect the body from overreacting to harmless particles such as dust, pollen, or Aspergillus spores.

Tregs work by releasing interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), two powerful calming signals that suppress over-active helper T cells (Th2 and Th17) and reduce allergic or inflammatory damage.

🦠 Aspergillus and the Immune System

Everyone inhales Aspergillus spores daily.
In healthy people, the immune system quickly clears them. But in individuals with asthma, allergies, or lung damage, the immune response can become unbalanced:

Form of Aspergillosis	Main Immune Problem	Treg Function
Allergic Bronchopulmonary Aspergillosis (ABPA) / Severe Asthma with Fungal Sensitisation (SAFS)	The immune system over-reacts to Aspergillus allergens, causing inflammation, mucus plugging, and airway obstruction	Too few or weak Tregs → loss of immune control
Chronic Pulmonary Aspergillosis (CPA)	Ongoing fungal growth with persistent inflammation and fibrosis	Excess local Treg activity may dampen antifungal defence
Invasive Aspergillosis (IA)	Profound immune weakness (e.g., after chemotherapy, corticosteroids, or organ transplant)	Tregs can further suppress protective antifungal responses

⚖️ The Delicate Balance

The immune system must balance acceleration and braking:

Too little Treg control → allergic inflammation and tissue damage.
Too much Treg control → poor antifungal clearance and chronic infection.

The ideal is immune equilibrium — strong enough to fight Aspergillus, but calm enough to prevent lung injury.

💊 Treatments That Influence Regulatory T Cells

Several therapies already used for aspergillosis or severe asthma may influence Treg activity:

Therapy	Possible Effect on Tregs
Corticosteroids (e.g., prednisolone)	Reduce inflammation and may increase IL-10-producing Tregs
Biologic therapies (omalizumab, mepolizumab, dupilumab)	Indirectly restore Treg–Th2 balance by blocking overactive allergy pathways
Vitamin D supplementation	Promotes stable and functional Tregs; deficiency linked with severe ABPA
Healthy gut microbiome (dietary fibre, probiotics)	Gut–lung axis supports Treg generation via short-chain fatty acids
Low-dose interleukin-2 (IL-2) therapy (research stage)	Expands Tregs selectively — now in early clinical trials for allergic and autoimmune disease

🔬 Current Research Directions

Researchers are studying:

Differences in Treg profiles between ABPA, SAFS, CPA, and healthy lungs
How biologic therapies and antifungal drugs affect the Treg–Th2–Th17 balance
Whether IL-2-based immune modulation could calm allergic flares without immunosuppression
The influence of the airway microbiome on lung Treg activity

These studies aim for personalised immune therapy, tailoring treatment to each patient’s immune pattern.

💬 Take-Home Message

Regulatory T cells are the peacekeepers of the immune system.
Their discovery — now honoured by the 2025 Nobel Prize — transformed our understanding of allergy, infection, and autoimmunity.

In aspergillosis, restoring Treg balance could one day:

Calm allergic inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA)
Limit lung scarring and fibrosis in Chronic Pulmonary Aspergillosis (CPA)
Support better fungal control without harmful over-suppression

By understanding these immune “brakes,” researchers hope to keep both Aspergillus and the immune system under control — balanced, not overactive.

by GAtherton

🔍 Aspergillosis: Recent Highlights & Key Publications October 2025 (Week 41)

Revised ISHAM-ABPA working group guidelines (2024)

Scope & criteria: Codifies ABPA diagnosis around mandatory Aspergillus sensitisation (specific IgE or SPT) plus total IgE ≥ 500 IU/mL, with supporting features (Aspergillus-specific IgG/precipitins, eosinophilia, imaging with central bronchiectasis/mucus plugging). Distinguishes ABPA vs. ABPM (other fungi) and sets clinical states (acute, response, exacerbation, remission).
Treatment pathways: For acute ABPA, permits oral corticosteroids or itraconazole as first-line; combination is reasonable in severe disease or frequent relapsers. Provides steroid-sparing strategies (itraconazole/voriconazole/posaconazole) and practical taper schedules.
Biologics & monitoring: Positions omalizumab/mepolizumab/dupilumab for recurrent/exacerbation-prone ABPA. Recommends multidimensional response criteria (symptoms, exacerbations, lung function, IgE kinetics, radiology) rather than IgE alone.
Paper (Eur Respir J) · PubMed · OA summary (PMC).

BTS Clinical Statement on Aspergillus-Related Chronic Lung Disease (2025)

Who it’s for: UK-focused guidance to help respiratory teams manage CPA, aspergilloma, chronic airway disease with Aspergillus, and allergic phenotypes in secondary care.
CPA approach: Emphasises radiology over time (HRCT), microbiology/Aspergillus-IgG, and exclusion of mimics (NTM, malignancy). Advises long-term azoles (with TDM & LFTs), and when to consider surgery (haemoptysis/aspergilloma).
Service model: Encourages early referral/MDT (radiology, mycology, thoracic surgery, interventional radiology), signposts NAC pathways, and sets pragmatic follow-up intervals (clinical, radiology, serology).
BTS page · News item · (access via Thorax from BTS page).

Consensus guidelines for invasive aspergillosis (ECMM/ISHAM CAPA; 2021)

Definitions: Introduces proven/probable/possible CAPA using clinical + mycological evidence (BAL/TA culture or PCR, GM thresholds, imaging).
ICU nuance: Acknowledges non-neutropenic ICU patients (COVID/influenza) can develop IA with atypical imaging and lower fungal burdens; endorses combined biomarker strategies (BAL GM/PCR ± serum GM).
Therapy: Positions voriconazole/isavuconazole as first-line; L-AmB where resistance or intolerance suspected. Flags early initiation on high suspicion to improve outcomes.
Paper (Lancet Infect Dis) · PubMed · ECMM guideline hub.

Epidemiology & Clinical Cohorts

Marseille 2-year retrospective cohort — CPA & ABPA insights (2025)

Design: Single-centre retrospective study applying ESCMID CPA criteria and modified ISHAM ABPA criteria to consecutive referrals.
Findings: High rate of diagnostic overlap (allergy + chronic infection features). Delays to diagnosis common, especially where IgG negative/indeterminate but GM/BAL/PCR positive.
Implication: Supports multimodal testing (serology, GM/PCR, serial imaging) and repeat sampling in indeterminate cases; highlights value of centre-based MDT.
PubMed · (preprint/alt copies if needed: SSRN/other listing, ResearchGate record).

Invasive aspergillosis in ICU settings (2025 review)

Epidemiology: IA increasingly reported in severe viral pneumonias (COVID, influenza); mortality ~40–50% depending on definition and antifungal timing.
Diagnostics: BAL GM outperforms serum GM in non-neutropenic ICU; PCR adds sensitivity but needs pre-test probability framing to avoid over-calling colonisation.
Care points: Advocate protocolised screening (e.g., twice-weekly BAL GM/PCR in high-risk ventilated patients) and earlier empiric therapy when criteria met.
Open access review (Frontiers, 2025) · (alt listing: ResearchGate record).

Review: Invasive aspergillosis — scope & new species (2024)

Landscape: Expands on non-fumigatus Aspergillus species, cryptic species with distinct susceptibility patterns, and emerging hosts (advanced COPD, cirrhosis, ICU).
Resistance: Summarises azole resistance mechanisms (cyp51A variants, TR34/L98H, TR46/Y121F/T289A) and notes environmental selection via triazole fungicides.
Practice: Reinforces susceptibility testing and situational use of L-AmB or isavuconazole where resistance is likely.
Review (ScienceDirect).

Diagnostics: Biomarkers, Molecular, Imaging & Novel Methods

GM antigen & Aspergillus IgG negative “escape” cases

Problem: In suspected CPA/airway disease, Aspergillus-IgG can be false-negative early or in immunomodulated hosts.
Finding: High GM titres (especially BAL) can help “rescue” such cases, prompting treatment or further invasive sampling.
Clinical use: In IgG-negative but high-suspicion scenarios, pair BAL GM + PCR and repeat serology; avoid reliance on single negative IgG.
OA study (2025) · PubMed. (See also general GM/BDG performance review: Medicine 2024).

Molecular diagnosis, qPCR & NGS advances (2025 review)

Performance: qPCR improves sensitivity vs culture/microscopy; specificity hinges on contamination control and clinical context.
Best practice: Combine qPCR with GM/BDG in high-risk patients; consider cycle thresholds and duplicate positivity to support true infection.
NGS: Useful for broad pathogen screens or resistant/cryptic species; needs standardisation and careful interpretation.
OA review (Front Cell Infect Microbiol, 2025). British Thoracic Society

Microscopy, GM, PCR comparative pilot (2025)

Design: Head-to-head assay comparison across serum/BAL/sputum against a composite clinical reference.
Takeaway: No single test is definitive; dual-modality (e.g., BAL GM + PCR) yields best balance. Microscopy remains specific but insensitive.
Study (ScienceDirect). ERS Publications

Emerging spectroscopy / imaging techniques (TERS)

What it is: Tip-enhanced Raman spectroscopy mapping conidial wall components (melanin, polysaccharides, proteins) at nanoscale.
Why it matters: Potential to differentiate strains or track resistance-linked wall changes; currently preclinical, not diagnostic.
AIP Applied Physics Letters (2025) · arXiv preprint.

Therapeutics, Resistance & New Drugs

Olorofim (F901318) — Phase IIb results (2025)

Population: Refractory invasive mould disease (including azole-resistant Aspergillus), many salvage scenarios.
Efficacy: Global response ~29% (D42) and ~27% (D84); when counting stable disease, success rises to ~75% (D42) and ~63% (D84).
Safety: Transaminase elevations ~10%, mostly reversible with dose interruption/adjustment; no treatment-related deaths reported.
Use case: Salvage/compassionate therapy where standard options fail or resistance limits choices; monitor LFTs and DDIs.
PubMed · Lancet Infect Dis abstract. (Trial record: NCT03583164).

Review of olorofim in aspergillosis

MoA: Inhibits dihydroorotate dehydrogenase (DHODH), blocking de novo pyrimidine synthesis (novel class, no cross-resistance with azoles/echnocandins/AmB).
Signals: Case series in azole-resistant disease (incl. CGD) report clinical/radiologic remission; combination strategies under study.
Caveats: Access via trials/managed access; need phase III data and resistance surveillance under use pressure.
epocrates.com

Pipeline and alternative antifungals

Fosmanogepix (Gwt1 inhibitor): Oral/IV; activity against Candida/Aspergillus; CNS penetration promising; phase II positive signals.
Rezafungin (long-acting echinocandin): Weekly IV dosing enables OPAT; emerging real-world data in invasive disease and step-down.
Ibrexafungerp (tricohalose class/β-glucan): Oral; Aspergillus data limited (better for Candida), but combinations explored.
New azoles (isavuconazole real-world/TDM): Use where voriconazole intolerance or QT issues exist.
(See contemporary reviews; real-world rezafungin data below.)

Rezafungin (real-world, 2025) — OPAT-friendly weekly echinocandin; emerging safety/utility data.

OA FungiScope study (Mycoses 2025) ·

Azole resistance & clinical implications

Drivers: Agricultural triazoles select environmental cyp51A mutations; patients can acquire primary resistant strains.
Practice changes: Where resistance prevalence is ≥10%, consider empiric L-AmB or isavuconazole until susceptibility known; always request AFST when feasible.
Nature Communications 2024 · Review PubMed.

Therapeutic drug monitoring & combination strategies

TDM: Essential for voriconazole/posaconazole (target troughs, avoid toxicity). Isavuconazole TDM less routine, but consider in extremes.
Combinations: Azole + echinocandin in refractory disease or high burden IA; AmB-based combos when resistance suspected. Evidence heterogeneous—use in expert-guided salvage.
(Covered within recent IA/therapy reviews above.)

Immunology, Host Responses & Biologics

Immunopathogenesis review (2023)

Pathways: Th2-skewed responses drive ABPA/SAFS (IgE/eosinophilia); defects in phagocyte function (neutropenia, CGD, high-dose steroids) predispose to invasive disease.
Mediators: Roles for IFN-γ, IL-5/IL-13, mucus hypersecretion, and airway remodelling; supports biologic targeting in allergic phenotypes.
OA review (Front Immunol 2023).

Biologics in ABPA / severe asthma

When to use: Relapsing ABPA, frequent steroid bursts, or steroid toxicity despite azole therapy.
Agents & effects: Omalizumab (anti-IgE) reduces exacerbations/steroid need; mepolizumab/benralizumab (anti-IL-5/IL-5R) tackle eosinophilia; dupilumab (anti-IL-4Rα) addresses Th2 axis and mucus/plugging.
Integration: Keep antifungal therapy for fungal burden; use biologics to control inflammation/exacerbations and spare steroids; monitor IgE dynamics and radiology.
ISHAM ABPA paper · PubMed.

by GAtherton

🌟 Biologics and the Future: A Toolkit for Severe Asthma, ABPA & Beyond

Many people with severe asthma or Allergic Bronchopulmonary Aspergillosis (ABPA) now have access to biologic medicines — treatments that block very specific signals in the immune system. For some, the results can feel miraculous. For others, the effect may fade or never fully take hold. But the exciting news is that science is building a toolkit of biologics that can be matched more closely to each person.

✨ Why biologics sometimes stop working

Biologics like tezepelumab (which blocks TSLP) can give dramatic improvements, but in some people the benefit doesn’t last.
That may be because the immune system “switches pathways” — other signals (like IL-5 or IL-13) start to dominate.
It doesn’t mean treatment is over — it means we need to try a different tool in the kit.

🧰 The current toolkit

Each biologic blocks a different “messenger” (called cytokines) in the immune system:

IgE blocker (omalizumab): helps in allergy-driven asthma/ABPA.
IL-5 / IL-5R blockers (mepolizumab, benralizumab, reslizumab, and soon depemokimab): reduce eosinophils (a type of white blood cell) that cause inflammation.
IL-4 / IL-13 blocker (dupilumab): controls type-2 inflammation, also helpful in eczema and nasal polyps.
TSLP blocker (tezepelumab): targets an “alarmin” high up in the pathway, useful across many asthma types.
IL-33 blockers (in development): another upstream “alarmin” that could help in the future.

🚀 What’s new and coming soon

Depemokimab: a long-acting IL-5 treatment, given only twice a year.
Inhaled anti-TSLP: same target as tezepelumab, but in inhaler form.
IL-33 blockers: still experimental, but promising because IL-33 is involved in fungal allergy and ABPA.

💡 What this means for ABPA

ABPA involves allergy (IgE), eosinophils (IL-5), and other signals like IL-33.
That’s why some patients respond to omalizumab, others to mepolizumab/benralizumab, others to dupilumab, and some to tezepelumab.
In the future, doctors may be able to choose the exact biologic (or even combination) that best matches your immune profile — just like targeted cancer treatments today.

🧩 The Biologic Toolkit (summary table)

Target Signal	Biologics	How it Helps	Relevance to ABPA
IgE (allergy antibody)	Omalizumab	Calms allergic reactions	Useful when IgE is high and fungus/allergy is a trigger
IL-5 / IL-5R (eosinophils)	Mepolizumab, Benralizumab, Reslizumab, Depemokimab (6-monthly)	Reduces eosinophils that damage lungs	Helpful in many ABPA patients with high eosinophils
IL-4 / IL-13 (type-2 inflammation)	Dupilumab	Reduces mucus, inflammation, and steroid need	Good in patients with eczema or nasal polyps alongside ABPA
TSLP (alarmin, upstream trigger)	Tezepelumab, Inhaled anti-TSLP (in trials)	Blocks an “early alarm” that activates many asthma pathways	Early evidence: big improvements in some ABPA patients
IL-33 / ST2 (alarmin)	Itepekimab, Astegolimab (in development)	Switches off another early “danger signal”	IL-33 is strongly linked to fungal allergy → promising for ABPA

🫁 COPD, Bronchiectasis & Mucus Plugging

COPD: Some biologics (like anti-IL-5) show benefit in patients with high eosinophils, and IL-33 blockers are being tested. Not yet routine NHS use.
Bronchiectasis: Biologics mainly help when asthma/ABPA overlap is present. Airway infections remain the bigger challenge.
Mucus plugging: Dupilumab can reduce mucus production. Other biologics may help indirectly, but airway clearance techniques remain essential.

💷 Why new medicines are expensive

Developing a new drug takes 10–15 years and can cost over £1 billion.
Most drugs fail — profits from a few successes must cover all the failures.
Patents give companies a period of exclusivity to recover costs, after which cheaper copies (generics or biosimilars) appear.

📊 Open market vs NHS

In the US (open market), companies set prices, and insurers or patients decide if they can pay → faster access, but very high costs and inequality.
In the UK (NHS), the system is funded by taxpayers. NICE weighs up cost vs benefit before approving drugs → slower access sometimes, but once approved, everyone gets it fairly.

🧬 Rare diseases and fungal infections

For rare diseases like ABPA and CPA, the market is too small to attract big pharma on profit alone.
Organisations like GAFFI (Global Action for Fungal Infections) and DNDi (Drugs for Neglected Diseases initiative) work with universities, charities, and governments to develop antifungals.
Examples:
- Olorofim (F2G, UK biotech): a brand-new antifungal class, developed with public and charity support.
- Rezafungin: a long-acting antifungal supported by government and public funding.
Without these partnership models, fungal drugs for ABPA/CPA would likely not exist.

🌈 The takeaway

Biologics are transforming treatment for asthma and ABPA — and new ones are coming.
If one biologic doesn’t work, others may.
COPD, bronchiectasis, and mucus plugging may also benefit in future.
New drugs are costly to develop, but the NHS negotiates to keep access fair.
For rare diseases like ABPA/CPA, partnerships and advocacy are crucial to get new drugs developed at all.

📖 Glossary of Acronyms

ABPA – Allergic Bronchopulmonary Aspergillosis
A lung condition caused by allergy to Aspergillus fungus, leading to inflammation, mucus plugging, and lung damage.

CPA – Chronic Pulmonary Aspergillosis
A long-term lung infection with Aspergillus fungus, usually in people with existing lung disease.

COPD – Chronic Obstructive Pulmonary Disease
A group of lung conditions (like chronic bronchitis and emphysema) that cause breathing difficulties.

NHS – National Health Service
The publicly funded healthcare system in the UK.

NICE – National Institute for Health and Care Excellence
The body that decides which treatments the NHS should fund, based on cost and benefit.

QALY – Quality-Adjusted Life Year
A way of measuring the benefit of a treatment: how much it improves both the length and quality of life.

IL – Interleukin
A type of messenger protein (cytokine) used by the immune system to trigger inflammation. Different ILs have numbers (IL-4, IL-5, IL-13, IL-33).

IgE – Immunoglobulin E
An antibody linked to allergies. Very high IgE levels are common in asthma and ABPA.

TSLP – Thymic Stromal Lymphopoietin
An “alarmin” (early danger signal) that tells the immune system to start reacting. Blocked by tezepelumab.

ST2 – Suppression of Tumorigenicity 2
The receptor for IL-33. Drugs like astegolimab block this pathway.

GAFFI – Global Action For Fungal Infections
A non-profit organisation pushing for better care, awareness, and research into fungal disease.

DNDi – Drugs for Neglected Diseases initiative
An international group that develops treatments for rare or overlooked diseases (including fungal infections).

EAMS – Early Access to Medicines Scheme
A UK programme that allows patients to use promising medicines before full approval.

FDA / EMA / MHRA – Food and Drug Administration (US) / European Medicines Agency (EU) / Medicines and Healthcare products Regulatory Agency (UK)
The agencies that approve and regulate medicines.

by GAtherton

💡 Dupilumab for ABPA: What You Need to Know Now the Trial Is Complete

A large Phase III trial—called LIBERTY‑ABPA AIRED—has recently completed studying dupilumab in people with ABPA and asthma who frequently exacerbate despite other treatments. Let’s break down what that means and what’s still missing 📌

🗓️ Trial Timeline & Scope

Trial completed: Primary data collection finished in July 2023, study closed in February 2024. It enrolled around 170 patients from over 30 sites across several countries including the UK, EU, US, Canada, Japan, and more Wikipedia+15trialsummaries.com+15Clinical Trials Register+15.
Design: Randomized, double‑blind, placebo‑controlled over 52 weeks, followed by 12 weeks safety follow‑up trialsummaries.comClinical Trials Register.

📋 What Was Measured?

The trial assessed:

Severe respiratory exacerbations (requiring steroids or hospital admission)
Lung function changes (e.g. FEV₁)
ABPA-related symptoms, quality of life, asthma control
Biomarkers including IgE and FeNO
Safety and tolerability, including antibody formation to dupilumab Wikipedia+15Clinical Trials+15trialsummaries.com+15

🧬 Why Results Matter

Dupilumab blocks both IL‑4 and IL‑13 pathways, which drive inflammation, mucus, and elevated IgE in ABPA. Early case reports and small series have shown promising benefits, especially in reducing exacerbations and steroid use, but until now, no large randomized trial data were available ScienceDirect+1PMC+1.

❓ What’s Available Now?

✅ The trial has finished, but official results have not yet been published or released publicly.
🕒 Regulators and sponsors previously estimated publication around late 2023, with actual report likely still under review or preparation ctv.veeva.com+3ScienceDirect+3Clinical Trials+3.
📡 Until these results are public, dupilumab remains not officially approved for ABPA, though individual clinicians may consider off‑label use in select cases.

🧾 Summary Table: Where Things Stand

Status	Current Position
Trial status	Completed Feb 2024
Official results	Pending publication
Based on early data	Case reports show improvement in exacerbations and steroid reduction
Regulatory status	Not yet licensed for ABPA treatment
Clinical use now	Only as part of research or off‑label under specialist review

💬 What Should Patients Do Now?

If you’re managing ABPA and considering biologic options:

✅ Ask if longstanding biologics like dupilumab are being considered for your individual case.
💬 Be clear that formal approval for ABPA is still pending, pending public release of the trial results.
🩺 Consult with your specialist or asthma/respiratory team about possible off‑label use—they can explain access options, benefits, and risks.

🧭 Final Thoughts

The LIBERTY‑ABPA AIRED trial has now completed, marking a major milestone for potential new treatment in ABPA. But until results are published and reviewed, dupilumab remains off-label for this condition.

You may still hear about its use in ABPA from case reports showing positive outcomes—but wider clinical acceptance awaits published study data. If it becomes available, it could offer meaningful benefits—but only if confirmed in research.

by GAtherton

🔬 Emerging Research for Aspergillosis

Aspergillosis is a complex group of diseases caused by the Aspergillus fungus. Ongoing research is uncovering new ways to diagnose, treat, and prevent these conditions—offering hope for improved care and long-term outcomes. This page outlines current areas of promising research relevant to patients, carers, and healthcare professionals.

⏱️ Has Research Accelerated Over Time?

Yes. Over the last 40 years, research into aspergillosis and fungal infections has significantly accelerated due to:

Rising awareness of fungal diseases in immunocompromised patients
Improved diagnostic technology (e.g. PCR, lateral flow tests, next-gen sequencing)
New drug development in response to growing azole resistance
Greater investment from both academic institutions and industry
Dedicated centres like the UK National Aspergillosis Centre driving specialist research
Fungal infections gaining WHO recognition as emerging public health threats

In the 1980s and 1990s, progress was relatively slow. Since the early 2000s—and especially after the COVID-19 pandemic revealed the risks of fungal co-infection—momentum has increased markedly.

1. 🧪 Antifungal Drug Development

Resistance to azole antifungals is a growing concern. Several new antifungal agents are in development:

🔸 Olorofim (F2G)

First-in-class orotomide antifungal
Shows activity against Aspergillus, including azole-resistant strains
Currently in phase III trials for invasive and chronic pulmonary aspergillosis

🔸 Ibrexafungerp and Fosmanogepix

New antifungals with different mechanisms of action
Potentially effective in combination or for resistant cases

🔸 Inhaled Antifungals

Trials of inhaled itraconazole, posaconazole, and PC945 (opelconazole) for direct delivery to the lungs
Aim: higher local drug concentrations with fewer side effects

2. 🧬 Biologics and Immune Modulation

🧭 What's Next in Biologic Therapies for Severe Asthma?

Several next-generation biologics are under development, aiming to:

Broaden coverage for patients who don't respond to existing biologics
Target upstream pathways (beyond IL‑5, IL‑4/13, or IgE)
Offer once-yearly dosing or dual-target activity

Examples include:

Depemokimab: A long-acting anti-IL‑5 antibody in phase 3 trials (GSK)
CSJ117: An inhaled anti-TSLP monoclonal antibody fragment (Novartis)
RG6354: Targeting IL-33 pathway, an upstream trigger in type 2 and non-type 2 asthma
Dual Biologics: Exploratory research combining two targets (e.g., IL‑5 + IL‑4 or TSLP + IL‑13)

These developments may also benefit subsets of aspergillosis patients with severe asthma or ABPA who have not fully responded to current biologics. Research is exploring biologic therapies that reduce allergic inflammation or modulate immune response, particularly for ABPA (Allergic Bronchopulmonary Aspergillosis) and overlapping asthma subtypes.

✅ Biologics Currently in Use for ABPA

Omalizumab (Xolair) – Anti-IgE

Target: IgE antibody—blocks allergic immune response to Aspergillus antigens.
Evidence: Studies show significant reductions in exacerbations, IgE, steroid use, and improved lung function.
Clinical Use: Widely used off-label in ABPA patients with raised IgE and asthma features.

Mepolizumab (Nucala) – Anti–IL‑5

Target: IL‑5 cytokine—reduces eosinophil inflammation.
Use: Steroid-sparing and symptom control in eosinophilic ABPA.

Benralizumab (Fasenra) – Anti–IL‑5 Receptor

Target: IL‑5Rα—causes rapid eosinophil depletion.
Use: Clearing mucus plugs and reducing flares; often used after mepolizumab failure.

Dupilumab (Dupixent) – Anti–IL‑4Ra

Target: IL‑4/IL‑13 pathway—type 2 inflammation.
Use: Shown to reduce IgE levels and ABPA exacerbations.

Tezepelumab (Tezspire) – Anti‑TSLP

Target: TSLP—broadly suppresses upstream allergic inflammation.
Evidence: Early reports suggest benefit in ABPA patients, though data are limited.

📊 Real-World Effectiveness

UK-based retrospective study (2014–2022):

74 ABPA patients treated with biologics
65% showed ≥50% reduction in steroid use after 12 months
35% switched due to lack of effect or side effects

📌 Summary Table of Biologics

Biologic	Target	Use in Aspergillosis	Key Benefits
Omalizumab	IgE	ABPA with raised IgE	↓ Exacerbations, ↓ steroids, ↑ FEV₁
Mepolizumab	IL‑5	Eosinophilic ABPA	Steroid-sparing, symptom control
Benralizumab	IL‑5Rα	Refractory cases	Mucus clearance, eosinophil depletion
Dupilumab	IL‑4/IL‑13	Mixed allergic/eosinophilic ABPA	↓ IgE, ↓ flares
Tezepelumab	TSLP	Emerging, broad asthma-ABPA	Broad inflammation control

3. 🧫 Diagnostic Advances

Improved diagnostics aim to detect disease earlier and more accurately:

Lateral flow tests (e.g., Aspergillus-specific LFD) for rapid diagnosis
PCR testing and galactomannan assays in blood, sputum, or BAL
Aspergillus-specific IgG and IgE testing to distinguish CPA, ABPA, and colonisation
Next-generation sequencing (NGS) for strain typing and resistance detection

4. 🌡️ Non-Pharmacological Research

🌀 Airway Clearance and Physiotherapy

Trials assessing flutter devices, oscillating PEP, and manual physiotherapy in chronic aspergillosis and bronchiectasis

🥦 Nutrition and Gut-Lung Health

Increasing interest in the role of dietary fibre, gut microbiome, and short-chain fatty acids in immune defence and lung inflammation

💨 Air Quality and Exposure

Home-based studies evaluating the impact of HEPA filters, spore counts, and environmental remediation

5. 🛡️ Preventative Strategies

🫁 Lung/Nasal Coatings (Experimental)

Early research into coating the lungs or nasal passages to prevent infection
Not yet in human trials for aspergillosis, but promising in animals for viral and bacterial prevention

💉 Vaccines

No approved vaccines yet, but exploratory work is underway for high-risk populations

6. 🧫 Clinical Trials in Aspergillosis

A wide range of clinical trials are currently underway or recently completed, focusing on new antifungals, biologics, and non-pharmacological interventions:

🧪 Antifungal Trials

Rezafungin – A long-acting echinocandin administered once weekly, currently in trials for prevention and treatment of invasive fungal infections, including those caused by Aspergillus species
Olorofim (F2G) – Phase III trials for CPA and invasive aspergillosis
PC945 (Opelconazole) – Inhaled triazole for CPA and prophylaxis in immunocompromised patients
Fosmanogepix and Ibrexafungerp – Investigated in resistant and invasive fungal disease

🧬 Biologic Trials

Tezepelumab and Dupilumab – Trials involving patients with ABPA and severe asthma
Depemokimab (GSK) – Phase III trials for long-acting IL‑5 blockade

🌡️ Other Trials

Airway clearance studies – Use of physiotherapy and flutter/PEP devices in chronic pulmonary aspergillosis
Gut microbiome and fibre supplementation – Exploring anti-inflammatory potential in lung disease

These trials often recruit patients from UK centres including the National Aspergillosis Centre, and are registered on databases such as ClinicalTrials.gov.

7. 🤝 Patient Support and Outcomes Research

📊 Real-World Evidence

Registries and observational studies (e.g., LIFE, FungiScope) gathering long-term data on patients with CPA, ABPA, SAFS, and invasive disease

👥 Quality of Life and Patient-Reported Outcomes

Surveys and tools to measure impact of fatigue, breathlessness, mental health, and medication side effects
Aim: improve personalised care and support services

🧭 Where to Find Updates

ClinicalTrials.gov – searchable by "aspergillosis"
Aspergillosis.org – for patient-friendly research summaries
National Aspergillosis Centre (UK) – involved in many UK-based studies
Journal of Fungi, Medical Mycology, Clinical Infectious Diseases – leading sources of peer-reviewed studies

📢 Final Word

Research into aspergillosis is accelerating across drug development, diagnostics, prevention, and patient support. While not all options are available yet, many are in trials or early clinical use. Staying informed and involved—whether through trial participation or feedback—helps shape better care for all.

Updated July 2025 – suitable for patients, clinicians, and advocacy groups.

by GAtherton

🫁 Could Lung or Nasal Coatings Help Prevent Aspergillosis?

As research into new ways of preventing lung infections advances, some patients with aspergillosis are asking whether coating the lungs or airways—with a protective spray, gel, or surfactant—might one day protect them from fungal disease.

Here’s what the science says so far.

🔬 What Is Being Researched?

Scientists are currently studying ways to coat the lungs or nasal passages with a protective substance designed to:

Trap or neutralise viruses, bacteria, or fungal spores
Stabilise the lung or airway lining
Prevent inflammation or infection from taking hold

These coatings may come in the form of:

Dry powder aerosols (inhaled)
Drug-free nasal gels or sprays

Importantly, these are being developed as preventative measures, not as treatments for people already ill.

🧪 Current Research: Early-Stage, Not Yet for Aspergillosis

1. Dry Powder Lung Surfactants

These are based on natural surfactants that coat the lungs and keep the air sacs (alveoli) open.
Tested in animals (e.g., lambs, rabbits) with good results in preventing respiratory distress or injury.
Used mostly in neonatal care for premature babies.
Not yet tested for fungal infections or chronic diseases like aspergillosis.

2. Nasal Gel-Coating Sprays

These sprays form a temporary coating in the nose and upper airways, shown in mice to block viruses like flu or COVID-19.
Protective effect may last several hours.
Still in animal testing—no human trials or approvals yet.
No evidence yet that they can prevent fungal infections like Aspergillus.

📌 Are These Coatings Available Yet?

No. As of now:

There are no licensed lung or nasal sprays designed to prevent aspergillosis or other fungal lung infections.
Most studies are in pre-clinical stages (animal research only).
It may be several years before any human trials begin.

🛡️ Who Might Receive These Preventatives in the Future?

If future research proves these coatings are safe and effective, likely priority groups would include:

🎯 High-risk populations:

People with chronic aspergillosis (CPA) or ABPA
Patients on long-term steroids or immunosuppressants
Individuals with bronchiectasis, COPD, or cystic fibrosis
Transplant recipients or those with cancer or immune deficiencies
Elderly people, especially in care homes
Healthcare or construction workers exposed to dust, spores, or mould
Hospitalised or ventilated patients (e.g. risk of CAPA in ICU)

❗ What Aspergillosis Patients Should Know

These technologies are not available yet and remain in the research phase.
They are being explored as preventative tools, not as treatment for existing fungal infections.
There is no evidence yet they can prevent Aspergillus infections—but the research is promising.

✅ What You Can Do Now

Until better preventatives are developed, people with aspergillosis can reduce risk by:

Avoiding high-risk environments (e.g., compost, renovation dust, decaying vegetation)
Using prescribed antifungals or steroids correctly
Supporting immune health (e.g., good nutrition, rest, fibre-rich diet)
Asking doctors about biologics or ongoing research trials if relevant

📘 Final Word

While the idea of coating the lungs or nose to stop infections sounds futuristic, it’s grounded in real science. For people vulnerable to fungal lung disease, this kind of innovation may one day offer protection—especially for those on immunosuppressive treatments or with fragile lungs.

But for now, the best defence remains personalised treatment, avoidance strategies, and good communication between specialists and GPs. We’ll keep watching this space closely as research develops.

by GAtherton